inTEST Reports Record $123.3 Million in Revenue and Net Income of $9.3 Million for Full Year 2023
- None.
- None.
Insights
The reported financial results show a mixed picture for inTEST Corporation. While the annual revenue growth of 6% and net income increase of 10% are positive indicators, the decline in fourth quarter revenue by 14% year-over-year raises concerns. The growth in defense/aerospace and industrial markets is a positive sign of diversification, which can help stabilize the company against the volatility of the semiconductor market. However, the contraction in gross margin and the decrease in operating income suggest potential challenges in cost management or pricing pressures.
The acquisition of Alfamation could be seen as a strategic move to enhance test and automation capabilities and expand market presence. Investors should monitor how this acquisition integrates with inTEST's operations and whether it contributes to revenue growth and margin improvement as anticipated. The cash flow generation is robust and the solid balance sheet with a significant cash increase and debt reduction provides financial flexibility. This could be beneficial for pursuing further growth initiatives or weathering potential market downturns.
The industrial and defense/aerospace sectors have shown resilience and growth for inTEST Corporation, which is a testament to the company's market diversification strategy. The semiconductor sector's reported weakness is a known industry trend and inTEST's ability to offset this with strength in other markets is noteworthy. The acquisition of Alfamation and the establishment of a new Center of Excellence in Malaysia indicate a proactive approach to capturing market opportunities and expanding global reach.
Looking ahead, the projected revenue range for 2024 suggests cautious optimism, factoring in the Alfamation acquisition. The company's focus on innovation and talent attraction is likely aimed at maintaining competitive advantage and driving organic growth. Investors should consider the potential of these strategic moves to contribute to long-term value creation.
inTEST Corporation's financial performance reflects broader economic trends, such as the cyclical nature of the semiconductor market and the impact of global supply chain challenges. The company's strong operational cash flow and increased cash reserves indicate a healthy liquidity position, which is important in navigating economic uncertainties. The debt reduction also suggests prudent financial management.
The company's guidance for the first quarter of 2024, including the Alfamation acquisition, shows expected stability in gross margin and a slight increase in operating expenses. This guidance, along with the effective tax rate and share count, will be key factors for investors to consider when evaluating the company's near-term financial health and earnings potential.
-
2023 revenue increased
6% year-over-year while net income grew10% -
Demonstrated strong operational cash flow: generated
in cash from operations in the fourth quarter and a record$4.7 million for the year$16.2 million - Market diversification provided strength in sales for the year supported by growth in defense/aerospace, industrial, security and life sciences markets
-
Fourth quarter orders improved
2% over the prior quarter driven by defense/aerospace and industrial markets -
Expects 2024 revenue to range from
to$145 million including the acquisition of Alfamation$155 million
“The effective execution of our 5-Point Strategy continues to drive strong results as we delivered a second consecutive year of record revenue while also achieving net income of
Mr. Grant added, “The recent acquisition of Alfamation, which we announced on March 12, 2024, is further proof of the progress we are making on our 5-Point Strategy. The acquisition adds significant test and automation capabilities, broadens geographic and key market presence while also providing measurable scale to the Electronic Test division. The team will continue to drive organic growth initiatives while pursuing highly complementary acquisitions such as Alfamation.”
Fourth Quarter 2023 Review (see revenue by market and by segments in accompanying tables)
Three Months Ended |
|||||||
($ in 000s) |
Change |
Change |
|||||
12/31/2023 |
12/31/2022 |
$ |
% |
9/30/2023 |
$ |
% |
|
Revenue |
|
|
|
- |
|
|
- |
Gross profit |
|
|
|
- |
|
|
- |
Gross margin |
|
|
|
||||
Operating expenses (incl. intangible amort.) |
|
|
|
|
|
|
- |
Operating income |
|
|
|
- |
|
|
- |
Operating margin |
|
|
|
||||
Net earnings |
|
|
|
- |
|
|
- |
Net margin |
|
|
|
|
|
|
|
Earnings per diluted share (“EPS”) |
|
|
|
- |
|
|
- |
Adjusted net earnings (Non-GAAP) (1) |
|
|
|
- |
|
|
- |
Adjusted EPS (Non-GAAP) (1) |
|
|
|
- |
|
|
- |
Adjusted EBITDA (Non-GAAP) (1) |
|
|
|
- |
|
|
- |
Adjusted EBITDA margin (Non-GAAP) (1) |
|
|
|
(1) Adjusted net earnings, adjusted EPS, adjusted EBITDA, and adjusted EBITDA margin are non-GAAP financial measures. Further information can be found under “Non-GAAP Financial Measures.” See also the reconciliations of GAAP financial measures to non-GAAP financial measures that accompany this press release.
Compared with the prior-year period, fourth quarter revenue was down primarily due to
Gross margin was
With the benefit of other income in the quarter of
2023 Summary
Full year revenue was a record
Gross profit for the year increased
Net earnings benefitted from higher cash balances and interest rates resulting in other income of
Significant Financial Flexibility with Strong Cash Flow and a Solid Balance Sheet
The Company generated
Cash and cash equivalents at December 31, 2023 were
Fourth Quarter 2023 Orders and Backlog (see orders by market in accompanying tables)
|
Three Months Ended |
||||||
($ in 000s) |
|
|
Change |
|
Change |
||
|
12/31/2023 |
12/31/2022 |
$ |
% |
9/30/2023 |
$ |
% |
Orders |
|
|
|
- |
|
|
|
Backlog (at quarter end) |
|
|
|
- |
|
|
- |
Fourth quarter orders of
Backlog at December 31, 2023, was
Orders and backlog are key performance metrics that management uses to analyze and measure the Company’s financial performance and results of operations. Please see “Key Performance Indicators” for a further explanation of the use and how these metrics are calculated.
First Quarter and Full Year 2024 Guidance
First quarter guidance now includes just over two weeks of financial results from the Alfamation acquisition. Revenue for the first quarter of 2024 is expected to be approximately
First quarter 2024 estimated EPS is now expected to be approximately
1Adjusted earnings per diluted share is a non-GAAP financial measure. Further information can be found under “Non-GAAP Financial Measures.” See also the reconciliations of GAAP financial measures to non-GAAP financial measures that accompany this press release.
2 First quarter 2024 estimated adjusted EPS is a forward-looking non-GAAP financial measure. Further information can be found under “Forward-looking Non-GAAP Financial Measures.” See also the reconciliations of GAAP financial measures to non-GAAP financial measures that accompany this press release.
The Company’s guidance for 2024 is as follows:
(as of March 27, 2024) |
2024 Guidance |
Revenue |
|
Gross margin |
|
Operating expenses |
|
Intangible asset amort expense |
Approximately |
Intangible asset amort exp. after tax |
Approximately |
Effective tax rate |
|
Capital expenditures |
|
The foregoing guidance is based on management’s current views with respect to operating and market conditions and customers’ forecasts. It also assumes macroeconomic conditions remain unchanged through the end of the year and does not consider any extraordinary non-operating expenses that may occur from time to time. Actual results may differ materially from what is provided here today because of, among other things, the factors described under “Forward-Looking Statements” below. Further information about non-GAAP measures can be found under “Non-GAAP Financial Measures” and the reconciliations of GAAP financial measures to non-GAAP financial measures that accompany this press release.
Conference Call and Webcast
The Company will host a conference call and webcast tomorrow, March 28, 2024 at 8:30 a.m. ET. During the conference call, management will review the financial and operating results and discuss inTEST’s corporate strategy and outlook. A question-and-answer session will follow. To listen to the live call, dial (201) 689-8263. In addition, the webcast and slide presentation may be found at www.intest.com/investor-relations.
A telephonic replay will be available from 11:30 a.m. ET on the day of the call through Thursday, April 4, 2024. To listen to the archived call, dial (412) 317-6671 and enter replay pin number 13745436. The webcast replay can be accessed via the investor relations section of www.intest.com, where a transcript will also be posted once available.
About inTEST Corporation
inTEST Corporation is a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets including automotive/EV, defense/aerospace, industrial, life sciences, and security, as well as both the front-end and back-end of the semiconductor manufacturing industry. Backed by decades of engineering expertise and a culture of operational excellence, inTEST solves difficult thermal, mechanical, and electronic challenges for customers worldwide while generating strong cash flow and profits. inTEST’s strategy leverages these strengths to grow organically and with acquisitions through the addition of innovative technologies, deeper and broader geographic reach, and market expansion. For more information, visit www.intest.com.
Non-GAAP Financial Measures and Forward-Looking Non-GAAP Financial Measures
In addition to disclosing results that are determined in accordance with generally accepted accounting practices in
Definition of Non-GAAP Measures
The Company defines these non-GAAP measures as follows:
- Adjusted net earnings is derived by adding acquired intangible amortization, adjusted for the related income tax expense (benefit), to net earnings.
- Adjusted earnings per diluted share (adjusted EPS) is derived by dividing adjusted net earnings by diluted weighted average shares outstanding.
- Adjusted EBITDA is derived by adding acquired intangible amortization, net interest expense, income tax expense, depreciation, and stock-based compensation expense to net earnings.
- Adjusted EBITDA margin is derived by dividing adjusted EBITDA by revenue.
These results are provided as a complement to the results provided in accordance with GAAP. Adjusted net earnings and adjusted earnings per diluted share (adjusted EPS) are non-GAAP financial measures presented to provide investors with meaningful, supplemental information regarding our baseline performance before acquired intangible amortization charges as management believes this expense may not be indicative of our underlying operating performance. Adjusted EBITDA and adjusted EBITDA margin are non-GAAP financial measures presented primarily as a measure of liquidity as they exclude non-cash charges for acquired intangible amortization, depreciation and stock-based compensation. In addition, adjusted EBITDA and adjusted EBITDA margin also exclude the impact of interest income or expense and income tax expense or benefit, as management believes these expenses may not be indicative of our underlying operating performance.
Management’s Use of Non-GAAP Measures
The non-GAAP financial measures presented in this press release are used by management to make operational decisions, to forecast future operational results, and for comparison with our business plan, historical operating results and the operating results of our peers. Reconciliations from net earnings and earnings per diluted share (EPS) to adjusted net earnings and adjusted earnings per diluted share (adjusted EPS) and from net earnings and net margin to adjusted EBITDA and adjusted EBITDA margin, are contained in the tables below.
Limitations of adjusted net earnings, adjusted earnings per diluted share (adjusted EPS), adjusted EBITDA, and adjusted EBITDA margin
Each of our non-GAAP measures have limitations as analytical tools. They should not be viewed in isolation or as a substitute for GAAP measures of earnings or cash flows. Limitations may include the cash portion of interest expense, income tax (benefit) provision, charges related to intangible asset amortization and stock-based compensation expense. These items could significantly affect our financial results.
Management believes these Non-GAAP financial measures are important in evaluating our performance, results of operations, and financial position. We use non-GAAP financial measures to supplement our GAAP results to provide a more complete understanding of the factors and trends affecting our business.
Adjusted net earnings, adjusted earnings per diluted share (adjusted EPS), adjusted EBITDA, and adjusted EBITDA margin are not alternatives to net earnings, earnings per diluted share or margin as calculated and presented in accordance with GAAP. As such, they should not be considered or relied upon as substitutes or alternatives for any such GAAP financial measure. We strongly urge you to review the reconciliations of adjusted net earnings, adjusted earnings per diluted share (adjusted EPS), adjusted EBITDA, and adjusted EBITDA margin along with our financial statements included elsewhere in this press release. We also strongly urge you not to rely on any single financial measure to evaluate our business. In addition, because adjusted net earnings, adjusted earnings per diluted share (adjusted EPS), adjusted EBITDA, and adjusted EBITDA margin are not measures of financial performance under GAAP and are susceptible to varying calculations, the adjusted net earnings, adjusted earnings per diluted share (adjusted EPS), adjusted EBITDA, and adjusted EBITDA margin measures as presented in this press release may differ from and may not be comparable to similarly titled measures used by other companies.
Forward-Looking Non-GAAP Financial Measures
This release includes certain forward-looking non-GAAP financial measures, including estimated adjusted earnings per diluted share (estimated adjusted EPS). We have provided these non-GAAP measures for future guidance for the same reasons that were outlined above for historical non-GAAP measures.
We have reconciled non-GAAP forward-looking estimated adjusted EPS to its most directly comparable GAAP measure. The reconciliation from estimated net earnings per diluted share (EPS) to estimated adjusted EPS is contained in the table below.
Key Performance Indicators
In addition to the foregoing non-GAAP measures, management uses orders and backlog as key performance metrics to analyze and measure the Company’s financial performance and results of operations. Management uses orders and backlog as measures of current and future business and financial performance, and these may not be comparable with measures provided by other companies. Orders represent written communications received from customers requesting the Company to provide products and/or services. Backlog is calculated based on firm purchase orders we receive for which revenue has not yet been recognized. Management believes tracking orders and backlog are useful as it often is a leading indicator of future performance. In accordance with industry practice, contracts may include provisions for cancellation, termination, or suspension at the discretion of the customer.
Given that each of orders and backlog are operational measures and that the Company's methodology for calculating orders and backlog does not meet the definition of a non-GAAP measure, as that term is defined by the
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements do not convey historical information but relate to predicted or potential future events and financial results, such as statements of the Company’s plans, strategies and intentions, or our future performance or goals, that are based upon management's current expectations. These forward-looking statements can often be identified by the use of forward-looking terminology such as “believe,” “could,” “expects,” “guidance,” “may,” “will,” “should,” “plan,” “potential,” “forecasts,” “targets,” “estimates,” or similar terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, any mentioned in this press release as well as the Company’s ability to execute on its 5-Point Strategy, realize the potential benefits of acquisitions and successfully integrate any acquired operations, grow the Company’s presence in its key target and international markets, manage supply chain challenges, convert backlog to sales and to ship product in a timely manner; the success of the Company’s strategy to diversify its markets; the impact of inflation on the Company’s business and financial condition; indications of a change in the market cycles in the semi market or other markets served; changes in business conditions and general economic conditions both domestically and globally including rising interest rates and fluctuation in foreign currency exchange rates; changes in the demand for semiconductors; access to capital and the ability to borrow funds or raise capital to finance potential acquisitions or for working capital; changes in the rates and timing of capital expenditures by the Company’s customers; and other risk factors set forth from time to time in the Company’s Securities and Exchange Commission filings, including, but not limited to, the Annual Report on Form 10-K for the year ended December 31, 2023. Any forward-looking statement made by the Company in this press release is based only on information currently available to management and speaks to circumstances only as of the date on which it is made. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events, except as required by law.
– FINANCIAL TABLES FOLLOW –
inTEST CORPORATION
|
||||||||||||||||
|
|
Three Months Ended
|
|
Years Ended
|
|
|||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
|
2022 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
|
$ |
27,884 |
|
|
$ |
32,405 |
|
|
$ |
123,302 |
|
|
$ |
116,828 |
|
Cost of revenue |
|
|
15,435 |
|
|
|
17,424 |
|
|
|
66,324 |
|
|
|
63,388 |
|
Gross profit |
|
|
12,449 |
|
|
|
14,981 |
|
|
|
56,978 |
|
|
|
53,440 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling expense |
|
|
4,194 |
|
|
|
4,405 |
|
|
|
17,605 |
|
|
|
15,903 |
|
Engineering and product development expense |
|
|
1,929 |
|
|
|
1,880 |
|
|
|
7,618 |
|
|
|
7,529 |
|
General and administrative expense |
|
|
5,217 |
|
|
|
4,664 |
|
|
|
21,316 |
|
|
|
19,287 |
|
Total operating expenses |
|
|
11,340 |
|
|
|
10,949 |
|
|
|
46,539 |
|
|
|
42,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
1,109 |
|
|
|
4,032 |
|
|
|
10,439 |
|
|
|
10,721 |
|
Interest expense |
|
|
(153 |
) |
|
|
(178 |
) |
|
|
(679 |
) |
|
|
(635 |
) |
Other income |
|
|
610 |
|
|
|
27 |
|
|
|
1,288 |
|
|
|
59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income tax expense |
|
|
1,566 |
|
|
|
3,881 |
|
|
|
11,048 |
|
|
|
10,145 |
|
Income tax expense |
|
|
111 |
|
|
|
637 |
|
|
|
1,706 |
|
|
|
1,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings |
|
$ |
1,455 |
|
|
$ |
3,244 |
|
|
$ |
9,342 |
|
|
$ |
8,461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per common share – basic |
|
$ |
0.12 |
|
|
$ |
0.30 |
|
|
$ |
0.82 |
|
|
$ |
0.79 |
|
Weighted average common shares outstanding – basic |
|
|
11,962,679 |
|
|
|
10,725,662 |
|
|
|
11,461,399 |
|
|
|
10,673,017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per common share – diluted |
|
$ |
0.12 |
|
|
$ |
0.30 |
|
|
$ |
0.79 |
|
|
$ |
0.78 |
|
Weighted average common shares and common share equivalents outstanding – diluted |
|
|
12,122,099 |
|
|
|
10,928,220 |
|
|
|
11,779,912 |
|
|
|
10,862,538 |
|
inTEST CORPORATION
|
||||||||
|
|
December 31, |
||||||
|
|
|
2023 |
|
|
|
2022 |
|
ASSETS |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
45,260 |
|
|
$ |
13,434 |
|
Restricted cash |
|
|
- |
|
|
|
1,142 |
|
Trade accounts receivable, net of allowance for credit losses of |
|
|
18,175 |
|
|
|
21,215 |
|
Inventories |
|
|
20,089 |
|
|
|
22,565 |
|
Prepaid expenses and other current assets |
|
|
2,254 |
|
|
|
1,695 |
|
Total current assets |
|
|
85,778 |
|
|
|
60,051 |
|
Property and equipment: |
|
|
|
|
||||
Machinery and equipment |
|
|
7,118 |
|
|
|
6,625 |
|
Leasehold improvements |
|
|
3,601 |
|
|
|
3,242 |
|
Gross property and equipment |
|
|
10,719 |
|
|
|
9,867 |
|
Less: accumulated depreciation |
|
|
(7,529 |
) |
|
|
(6,735 |
) |
Net property and equipment |
|
|
3,190 |
|
|
|
3,132 |
|
Right-of-use assets, net |
|
|
4,987 |
|
|
|
5,770 |
|
Goodwill |
|
|
21,728 |
|
|
|
21,605 |
|
Intangible assets, net |
|
|
16,596 |
|
|
|
18,559 |
|
Deferred tax assets |
|
|
1,437 |
|
|
|
280 |
|
Restricted certificates of deposit |
|
|
100 |
|
|
|
100 |
|
Other assets |
|
|
1,013 |
|
|
|
569 |
|
Total assets |
|
$ |
134,829 |
|
|
$ |
110,066 |
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Current portion of Term Note |
|
$ |
4,100 |
|
|
$ |
4,100 |
|
Current portion of operating lease liabilities |
|
|
1,923 |
|
|
|
1,645 |
|
Accounts payable |
|
|
5,521 |
|
|
|
7,394 |
|
Accrued wages and benefits |
|
|
4,156 |
|
|
|
3,907 |
|
Accrued professional fees |
|
|
1,228 |
|
|
|
884 |
|
Customer deposits and deferred revenue |
|
|
3,797 |
|
|
|
4,498 |
|
Accrued sales commission |
|
|
1,055 |
|
|
|
1,468 |
|
Domestic and foreign income taxes payable |
|
|
1,038 |
|
|
|
1,409 |
|
Other current liabilities |
|
|
1,481 |
|
|
|
1,564 |
|
Total current liabilities |
|
|
24,299 |
|
|
|
26,869 |
|
Operating lease liabilities, net of current portion |
|
|
3,499 |
|
|
|
4,705 |
|
Term Note, net of current portion |
|
|
7,942 |
|
|
|
12,042 |
|
Contingent consideration |
|
|
1,093 |
|
|
|
1,039 |
|
Deferred revenue, net of current portion |
|
|
1,331 |
|
|
|
- |
|
Other liabilities |
|
|
384 |
|
|
|
455 |
|
Total liabilities |
|
|
38,548 |
|
|
|
45,110 |
|
|
|
|
|
|
||||
Stockholders' equity: |
|
|
|
|
||||
Preferred stock, |
|
|
- |
|
|
|
- |
|
Common stock, |
|
|
122 |
|
|
|
111 |
|
Additional paid-in capital |
|
|
54,450 |
|
|
|
31,987 |
|
Retained earnings |
|
|
42,196 |
|
|
|
32,854 |
|
Accumulated other comprehensive earnings |
|
|
414 |
|
|
|
218 |
|
Treasury stock, at cost; 75,758 and 34,308 shares, respectively |
|
|
(901 |
) |
|
|
(214 |
) |
Total stockholders' equity |
|
|
96,281 |
|
|
|
64,956 |
|
Total liabilities and stockholders' equity |
|
$ |
134,829 |
|
|
$ |
110,066 |
|
inTEST CORPORATION
|
||||||||
|
|
Years Ended
|
||||||
|
|
|
2023 |
|
|
|
2022 |
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
||||
Net earnings |
|
$ |
9,342 |
|
|
$ |
8,461 |
|
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
4,683 |
|
|
|
4,734 |
|
Provision for excess and obsolete inventory |
|
|
544 |
|
|
|
771 |
|
Foreign exchange (gain) loss |
|
|
(9 |
) |
|
|
109 |
|
Amortization of deferred compensation related to stock-based awards |
|
|
2,047 |
|
|
|
1,787 |
|
Discount on shares sold under Employee Stock Purchase Plan |
|
|
31 |
|
|
|
36 |
|
Proceeds from sale of demonstration equipment, net of gain |
|
|
167 |
|
|
|
68 |
|
Loss on disposal of property and equipment |
|
|
11 |
|
|
|
- |
|
Deferred income tax benefit |
|
|
(1,157 |
) |
|
|
(1,659 |
) |
Adjustment to contingent consideration liability |
|
|
(294 |
) |
|
|
- |
|
Changes in assets and liabilities: |
|
|
|
|
||||
Trade accounts receivable |
|
|
2,991 |
|
|
|
(4,886 |
) |
Inventories |
|
|
2,027 |
|
|
|
(10,631 |
) |
Prepaid expenses and other current assets |
|
|
(535 |
) |
|
|
(243 |
) |
Other assets |
|
|
(686 |
) |
|
|
(2 |
) |
Operating lease liabilities |
|
|
(1,712 |
) |
|
|
(1,363 |
) |
Accounts payable |
|
|
(1,811 |
) |
|
|
2,875 |
|
Accrued wages and benefits |
|
|
231 |
|
|
|
(118 |
) |
Accrued professional fees |
|
|
339 |
|
|
|
(157 |
) |
Customer deposits and deferred revenue |
|
|
(759 |
) |
|
|
(1,464 |
) |
Accrued sales commission |
|
|
(421 |
) |
|
|
621 |
|
Domestic and foreign income taxes payable |
|
|
(371 |
) |
|
|
(573 |
) |
Other current liabilities |
|
|
231 |
|
|
|
184 |
|
Deferred revenue, net of current portion |
|
|
1,331 |
|
|
|
- |
|
Other liabilities |
|
|
(17 |
) |
|
|
61 |
|
Net cash provided by (used in) operating activities |
|
|
16,203 |
|
|
|
(1,389 |
) |
|
|
|
|
|
||||
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
||||
Payment of contingent consideration related to Z-Sciences acquisition |
|
|
- |
|
|
|
(179 |
) |
Refund of final working capital adjustment related to Acculogic |
|
|
- |
|
|
|
371 |
|
Purchase of property and equipment |
|
|
(1,291 |
) |
|
|
(1,365 |
) |
Purchase of short term investments |
|
|
- |
|
|
|
(3,494 |
) |
Sales of short term investments |
|
|
- |
|
|
|
3,494 |
|
Net cash used in investing activities |
|
|
(1,291 |
) |
|
|
(1,173 |
) |
|
|
|
|
|
||||
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
||||
Net proceeds from public offering of common stock |
|
|
19,244 |
|
|
|
- |
|
Repayments of Term Note |
|
|
(4,100 |
) |
|
|
(3,958 |
) |
Proceeds from stock options exercised |
|
|
978 |
|
|
|
38 |
|
Proceeds from shares sold under Employee Stock Purchase Plan |
|
|
174 |
|
|
|
197 |
|
Settlement of employee tax liabilities in connection with treasury stock transaction |
|
|
(687 |
) |
|
|
(10 |
) |
Net cash provided by (used in) financing activities |
|
|
15,609 |
|
|
|
(3,733 |
) |
|
|
|
|
|
||||
Effects of exchange rates on cash |
|
|
163 |
|
|
|
(324 |
) |
Net cash provided by (used in) all activities |
|
|
30,684 |
|
|
|
(6,619 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
14,576 |
|
|
|
21,195 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
45,260 |
|
|
$ |
14,576 |
|
Cash payments for: |
|
|
|
|
||||
Domestic and foreign income taxes |
|
$ |
3,240 |
|
|
$ |
3,924 |
|
|
|
|
|
|
||||
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: |
|
|
|
|
||||
Issuance of unvested shares of restricted stock |
|
$ |
1,601 |
|
|
$ |
1,138 |
|
Forfeiture of unvested shares of restricted stock |
|
|
(176 |
) |
|
|
(54 |
) |
|
|
|
|
|
inTEST CORPORATION
|
||||||||||
($ in 000s) |
Three Months Ended |
|||||||||
Change |
Change |
|||||||||
12/31/2023 |
12/31/2022 |
$ |
% |
9/30/2023 |
$ |
% |
||||
Revenue |
||||||||||
Semi |
|
|
|
|
|
- |
|
|
|
- |
Industrial |
5,911 |
|
2,179 |
|
3,732 |
|
2,456 |
|
3,455 |
|
Auto/EV |
3,981 |
|
2,805 |
|
1,176 |
|
1,775 |
|
2,206 |
|
Life Sciences |
878 |
|
1,006 |
|
(128) |
- |
1,330 |
|
(452) |
- |
Defense/Aerospace |
2,416 |
|
2,176 |
|
240 |
|
3,392 |
|
(976) |
- |
Security |
819 |
|
1,002 |
|
(183) |
- |
967 |
|
(148) |
- |
Other |
3,136 |
|
3,784 |
|
(648) |
- |
2,545 |
|
591 |
|
|
|
|
|
|
- |
|
|
|
- |
|
($ in 000s) |
Years Ended |
|||||
Change |
||||||
12/31/2023 |
12/31/2022 |
$ |
% |
|||
Revenue |
||||||
Semi |
|
|
|
|
|
- |
Industrial |
14,310 |
|
10,038 |
|
4,272 |
|
Auto/EV |
9,895 |
|
10,776 |
|
(881) |
- |
Life Sciences |
4,856 |
|
4,589 |
|
267 |
|
Defense/Aerospace |
12,537 |
|
7,006 |
|
5,531 |
|
Security |
3,688 |
|
3,241 |
|
447 |
|
Other |
12,281 |
|
12,756 |
|
(475) |
- |
|
|
|
|
|
|
|
inTEST CORPORATION
|
||||||||||
($ in 000s) |
Three Months Ended |
|||||||||
Change |
Change |
|||||||||
12/31/2023 |
12/31/2022 |
$ |
% |
9/30/2023 |
$ |
% |
||||
Orders |
||||||||||
Semi |
|
|
|
|
|
- |
|
|
|
|
Industrial |
3,445 |
|
2,657 |
|
788 |
|
1,637 |
|
1,808 |
|
Auto/EV |
1,822 |
|
1,660 |
|
162 |
|
3,051 |
|
(1,229) |
- |
Life Sciences |
877 |
|
2,027 |
|
(1,150) |
- |
931 |
|
(54) |
- |
Defense/Aerospace |
5,161 |
|
3,364 |
|
1,797 |
|
3,032 |
|
2,129 |
|
Security |
65 |
|
2,172 |
|
(2,107) |
- |
2,212 |
|
(2,147) |
- |
Other |
2,858 |
|
4,660 |
|
(1,802) |
- |
3,056 |
|
(198) |
- |
|
|
|
|
|
- |
|
|
|
|
|
($ in 000s) |
Years Ended |
|||||
Change |
||||||
12/31/2023 |
12/31/2022 |
$ |
% |
|||
Orders |
||||||
Semi |
|
|
|
|
|
- |
Industrial |
14,980 |
|
10,554 |
|
4,426 |
|
Auto/EV |
10,193 |
|
9,899 |
|
294 |
|
Life Sciences |
4,353 |
|
5,705 |
|
(1,352) |
- |
Defense/Aerospace |
13,386 |
|
10,261 |
|
3,125 |
|
Security |
2,945 |
|
4,386 |
|
(1,441) |
- |
Other |
11,478 |
|
15,701 |
|
(4,223) |
- |
|
|
|
|
|
- |
|
inTEST CORPORATION
|
|||||||||||||||
|
Three Months Ended
|
|
|
Years Ended
|
|
||||||||||
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
||||
Electronic Test |
$ |
8,105 |
|
|
$ |
11,236 |
|
|
$ |
41,016 |
|
|
$ |
40,219 |
|
Environmental Technologies |
|
7,623 |
|
|
|
8,041 |
|
|
|
30,801 |
|
|
|
30,172 |
|
Process Technologies |
|
12,156 |
|
|
|
13,128 |
|
|
|
51,485 |
|
|
|
46,437 |
|
Total Revenue |
$ |
27,884 |
|
|
$ |
32,405 |
|
|
$ |
123,302 |
|
|
$ |
116,828 |
|
Division operating income: |
|
|
|
|
|
|
|
|
|
|
|
||||
Electronic Test |
$ |
1,702 |
|
|
$ |
3,445 |
|
|
$ |
10,189 |
|
|
$ |
9,931 |
|
Environmental Technologies |
|
594 |
|
|
|
924 |
|
|
|
3,073 |
|
|
|
3,817 |
|
Process Technologies |
|
2,182 |
|
|
|
2,466 |
|
|
|
9,544 |
|
|
|
8,230 |
|
Total division operating income |
|
4,478 |
|
|
|
6,835 |
|
|
|
22,806 |
|
|
|
21,978 |
|
Corporate expenses |
|
(2,856 |
) |
|
|
(2,251 |
) |
|
|
(10,272 |
) |
|
|
(8,563 |
) |
Acquired intangible amortization |
|
(513 |
) |
|
|
(552 |
) |
|
|
(2,095 |
) |
|
|
(2,694 |
) |
Interest expense |
|
(153 |
) |
|
|
(178 |
) |
|
|
(679 |
) |
|
|
(635 |
) |
Other income |
|
610 |
|
|
|
27 |
|
|
|
1,288 |
|
|
|
59 |
|
Earnings before income tax expense |
$ |
1,566 |
|
|
$ |
3,881 |
|
|
$ |
11,048 |
|
|
$ |
10,145 |
|
inTEST CORPORATION
Reconciliation of Non-GAAP Financial Measures
(In thousands, except per share and percentage data)
(Unaudited)
Reconciliation of Net Earnings to Adjusted Net Earnings (Non-GAAP) and
Earnings Per Share – Diluted to Adjusted Earnings Per Share – Diluted (Non-GAAP):
Three Months Ended |
|||||||||||
12/31/2023 |
|
12/31/2022 |
|
9/30/2023 |
|||||||
|
|
||||||||||
Net earnings |
$ |
1,455 |
|
$ |
3,244 |
|
$ |
2,277 |
|
||
Acquired intangible amortization |
|
513 |
|
|
552 |
|
|
515 |
|
||
Tax adjustments |
|
(58 |
) |
|
(89 |
) |
|
(85 |
) |
||
Adjusted net earnings (Non-GAAP) |
$ |
1,910 |
|
$ |
3,707 |
|
$ |
2,707 |
|
||
Diluted weighted average shares outstanding |
|
12,122 |
|
|
10,928 |
|
|
12,212 |
|
||
Earnings per share – diluted: |
|||||||||||
Net earnings |
$ |
0.12 |
|
$ |
0.30 |
|
$ |
0.19 |
|
||
Acquired intangible amortization |
|
0.04 |
|
|
0.05 |
|
|
0.04 |
|
||
Tax adjustments |
─ |
|
(0.01 |
) |
|
(0.01 |
) |
||||
Adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.16 |
|
$ |
0.34 |
|
$ |
0.22 |
|
||
|
Years Ended |
|
||||||
12/31/2023 |
|
12/31/2022 |
|
|||||
|
|
|||||||
Net earnings |
$ |
9,342 |
|
$ |
8,461 |
|
||
Acquired intangible amortization |
|
2,095 |
|
|
2,694 |
|
||
Tax adjustments |
|
(324 |
) |
|
(447 |
) |
||
Adjusted net earnings (Non-GAAP) |
$ |
11,113 |
|
$ |
10,708 |
|
||
Diluted weighted average shares outstanding |
|
11,780 |
|
|
10,863 |
|
||
Earnings per share – diluted: |
||||||||
Net earnings |
$ |
0.79 |
|
$ |
0.78 |
|
||
Acquired intangible amortization |
|
0.18 |
|
|
0.25 |
|
||
Tax adjustments |
|
(0.03 |
) |
|
(0.04 |
) |
||
Adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.94 |
|
$ |
0.99 |
|
||
Reconciliation of Net Earnings to Adjusted EBITDA (Non-GAAP) and
Adjusted EBITDA Margin (Non-GAAP):
Three Months Ended |
||||||||
12/31/2023 |
|
12/31/2022 |
|
9/30/2023 |
||||
|
|
|||||||
Net earnings |
$ |
1,455 |
$ |
3,244 |
$ |
2,277 |
||
Acquired intangible amortization |
|
513 |
|
552 |
|
515 |
||
Net Interest expense (income) |
|
(340) |
|
164 |
|
(276) |
||
Income tax expense |
|
111 |
|
637 |
|
446 |
||
Depreciation |
|
255 |
|
245 |
|
262 |
||
Non-cash stock-based compensation |
|
424 |
|
414 |
|
544 |
||
Adjusted EBITDA (Non-GAAP) |
$ |
2,418 |
$ |
5,256 |
$ |
3,768 |
||
Revenue |
|
27,884 |
|
32,405 |
|
30,941 |
||
Net margin |
|
|
|
|
|
|
|
|
Adjusted EBITDA margin (Non-GAAP) |
|
|
|
|
|
|
||
|
Years Ended |
||||
12/31/2023 |
|
12/31/2022 |
|||
|
|||||
Net earnings |
$ |
9,342 |
$ |
8,461 |
|
Acquired intangible amortization |
|
2,095 |
|
2,694 |
|
Net Interest expense (income) |
|
(404) |
|
600 |
|
Income tax expense |
|
1,706 |
|
1,684 |
|
Depreciation |
|
1,021 |
|
810 |
|
Non-cash stock-based compensation |
|
2,047 |
|
1,787 |
|
Adjusted EBITDA (Non-GAAP) |
$ |
15,807 |
$ |
16,036 |
|
Revenue |
|
123,302 |
|
116,828 |
|
Net margin |
|
|
|
|
|
Adjusted EBITDA margin (Non-GAAP) |
|
|
|
|
|
Reconciliation of First Quarter 2024 Estimated Earnings Per Share – Diluted to
Estimated Adjusted Earnings Per Share – Diluted (Non-GAAP):
|
Q1 2024E |
|
|
|
|
Estimated earnings per share – diluted |
$ |
0.06 |
Estimated acquired intangible amortization |
|
0.05 |
Estimated tax adjustments |
|
(0.01) |
Estimated adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.10 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327716572/en/
inTEST Corporation
Duncan Gilmour
Chief Financial Officer and Treasurer
Tel: (856) 505-8999
Investors:
Deborah K. Pawlowski
Kei Advisors LLC
dpawlowski@keiadvisors.com
Tel: (716) 843-3908
Source: inTEST Corporation
FAQ
What was inTEST 's (INTT) revenue increase in 2023?
How much did inTEST (INTT) generate in cash from operations in Q4?
What market diversification strategy helped inTEST (INTT) boost sales?
What was the percentage increase in 4th quarter orders for inTEST (INTT)?